Stock Traders Buy High Volume of Illumina Put Options (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMNGet Free Report) saw some unusual options trading on Tuesday. Investors bought 5,128 put options on the company. This is an increase of 55% compared to the typical volume of 3,298 put options.

Illumina Stock Down 1.1 %

Shares of Illumina stock opened at $106.68 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market cap of $16.99 billion, a price-to-earnings ratio of -13.09 and a beta of 1.15. The firm’s 50-day moving average is $109.34 and its two-hundred day moving average is $125.92. Illumina has a 1 year low of $89.00 and a 1 year high of $195.64.

Illumina (NASDAQ:ILMNGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s revenue was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 EPS. As a group, research analysts expect that Illumina will post 0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently added to or reduced their stakes in ILMN. Trivant Custom Portfolio Group LLC raised its position in shares of Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the last quarter. VisionPoint Advisory Group LLC raised its holdings in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $37,000. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 132 shares during the period. Finally, Gradient Investments LLC grew its stake in Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research reports. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen reduced their target price on shares of Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a report on Thursday, June 6th. Jefferies Financial Group started coverage on shares of Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price on the stock. Barclays boosted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Finally, Robert W. Baird raised their price objective on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $157.62.

Get Our Latest Research Report on Illumina

Illumina Company Profile

(Get Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.